开云app官网登录入口网页版-官方正版

#idecabtagene vicleucel#

4篇内容 | 868人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1715512, encodeId=38f91e15512d6, content=<a href='/topic/show?id=9c959406fa' target=_blank style='color:#2F92EE;'>#idecabtagene vicleucel#</a>, objectTitle=NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果, objectType=article, longId=207624, objectId=eba320e6248f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba320e6248f, replyNumber=0, likeNumber=83, createdTime=2022-02-04, rootId=0, userName=12498ef1m41(暂无昵称), userId=753b31938391, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba320e6248f, moduleTitle=NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eba320e6248f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715511, encodeId=eef71e1551199, content=<a href='/topic/show?id=9c959406fa' target=_blank style='color:#2F92EE;'>#idecabtagene vicleucel#</a>, objectTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, objectType=article, longId=198425, objectId=61571984251d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61571984251d, replyNumber=0, likeNumber=61, createdTime=2020-09-26, rootId=0, userName=12498ef1m41(暂无昵称), userId=753b31938391, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61571984251d, moduleTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=61571984251d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715509, encodeId=0ec11e1550992, content=<a href='/topic/show?id=9c959406fa' target=_blank style='color:#2F92EE;'>#idecabtagene vicleucel#</a>, objectTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, objectType=article, longId=184397, objectId=4dad18439e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad18439e2a, replyNumber=0, likeNumber=69, createdTime=2020-08-30, rootId=0, userName=12498ef1m41(暂无昵称), userId=753b31938391, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad18439e2a, moduleTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4dad18439e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715510, encodeId=64801e155101d, content=<a href='/topic/show?id=9c959406fa' target=_blank style='color:#2F92EE;'>#idecabtagene vicleucel#</a>, objectTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, objectType=article, longId=191240, objectId=fac619124043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fac619124043, replyNumber=0, likeNumber=109, createdTime=2020-11-27, rootId=0, userName=12498ef1m41(暂无昵称), userId=753b31938391, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fac619124043, moduleTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fac619124043)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

idecabtagene vicleucel

2020-05-29

12498ef1m41(暂无昵称) (审核中...)

前往app查看评论内容

#idecabtagene vicleucel#

NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果

2022-02-04

12498ef1m41(暂无昵称) (审核中...)

前往app查看评论内容

#idecabtagene vicleucel#

CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA

2020-09-26

12498ef1m41(暂无昵称) (审核中...)

前往app查看评论内容

#idecabtagene vicleucel#

百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果

2020-08-30

12498ef1m41(暂无昵称) (审核中...)

前往app查看评论内容

#idecabtagene vicleucel#

CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤

2020-11-27

科室
- - 订阅+
  - 更多科室
工具
服务